EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

[11C]MeRo25, a Unique Chemotype PET Radioligand, Shows Robust Brain Uptake but Insufficient Selectivity for GluN2B Imaging

Lisheng Cai, Jeih-San Liow, Xuefeng Yan, Cheryl L. Morse, Alyssa J. Wang, Leah N. Millard, Baku Acharya, Yonglan Liu, Sean W. Costner, Sami S. Zoghbi, Robert B. Innis, Victor W. Pike

Pharmaceuticals · 30.10.2026 · 19 (11) · 1713

DOI: 10.3390/ph19111713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 30.10.2026. Verfasst von Lisheng Cai und 11 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: GluN2B subunits of N-methyl-D-aspartate (NMDA) receptors are therapeutic targets for neuropsychiatric disorders, but an effective positron emission tomography (PET) radioligand for human GluN2B brain imaging is still needed. We developed [11C]MeRo25, a 11C-methylated derivative of the GluN2B-preferring ligand Ro 25-6981, and evaluated its suitability as a GluN2B PET radioligand.

Methods

MeRo25 was synthesized through methylation of Ro 25-6981, and affinities for GluN2B and σ1 receptors were determined in vitro. [11C]MeRo25 was prepared using [11C]methyl iodide. PET studies were performed in rats and monkeys at baseline and after challenge with GluN2B or σ1 receptor-directed ligands. In monkeys, regional total distribution volume (VT) was estimated through kinetic modeling.

Results

MeRo25 showed low nanomolar affinity for GluN2B and σ1 receptors. [11C]MeRo25 was obtained with a radiochemical yield of 20–30%, a purity of >99%, and high molar activity. [11C]MeRo25 showed rapid and high brain uptake in rats and monkeys. Pretreatment with either GluN2B or σ1 receptor-directed ligands in monkeys markedly reduced brain radioactivity and regional VT, demonstrating contributions from both receptor populations.

Conclusions

Despite favorable brain uptake and high GluN2B affinity, [11C]MeRo25 exhibits substantial σ1 receptor binding, producing a mixed GluN2B/σ1 receptor PET signal that precludes its use as a selective GluN2B radioligand. These findings emphasize the importance of in vivo pharmacological validation and reveal limitations of the Ro 25-6981 scaffold for selective GluN2B PET radioligand development. This study also cautions against the use of Ro 25-6981 as a pharmacological tool where binding to σ1 receptors may be of concern, for example as a challenge agent in PET studies.

Förderung

  • National Institutes of Health

Zitieren

APA

Cai, L., Liow, J., Yan, X., Morse, C. L., Wang, A. J., Millard, L. N., Acharya, B., Liu, Y., Costner, S. W., Zoghbi, S. S., Innis, R. B., & Pike, V. W. (2026). [11C]MeRo25, a Unique Chemotype PET Radioligand, Shows Robust Brain Uptake but Insufficient Selectivity for GluN2B Imaging. Pharmaceuticals, 19(11), 1713. https://doi.org/10.3390/ph19111713

Vancouver

Cai L, Liow J, Yan X, Morse CL, Wang AJ, Millard LN, et al. [11C]MeRo25, a Unique Chemotype PET Radioligand, Shows Robust Brain Uptake but Insufficient Selectivity for GluN2B Imaging. Pharmaceuticals. 2026;19(11):1713. doi:10.3390/ph19111713

BibTeX
@article{Cai2026,
  author = {Cai, Lisheng and Liow, Jeih-San and Yan, Xuefeng and Morse, Cheryl L. and Wang, Alyssa J. and Millard, Leah N. and Acharya, Baku and Liu, Yonglan and Costner, Sean W. and Zoghbi, Sami S. and Innis, Robert B. and Pike, Victor W.},
  title = {[11C]MeRo25, a Unique Chemotype PET Radioligand, Shows Robust Brain Uptake but Insufficient Selectivity for GluN2B Imaging},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1713},
  doi = {10.3390/ph19111713}
}
Kostenlos starten →